New JAMA Study Links Wegovy to NAION A JAMA study published on July 3, 2024, on the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide found an increased risk of the condition in patients taking semaglutide compared to those taking non-GLP-1 RA medications
In comparison, tirzepatide may provide even greater reduction potential, yet it is still undergoing assessment for long-term safety and effectiveness
Documented cases show that patients can be successfully treated with GLP-1 medications at 8 months after gallbladder removal, with good outcomes
Ltd., ProKidney, Roche, Vera, GSK, and Eli Lilly and Company
If you have significant weight to lose, semaglutide is the evidence-based choice
Once opened, it should be used within 56 days 7.5 Avoiding Contamination and Cross-Use Pens must not be shared between individuals, even with needle changes